GSK plc looks forward to investing $30 billion all across the U.S. in terms of research and development as well as supply chain infrastructure in the next five years. This happens to include a novel $1.2 billion investment when it comes to advanced manufacturing facilities along with AI and advanced digital technologies in order to deliver next-generation biopharma factories as well as labs across the U.S.
Apparently, the $1.2 billion investment goes on to include –
- Construction of an additional new biologics flex factory at Upper Merion, PA, so as to deliver potential best-in-class new medicines for respiratory diseases like COPD and asthma, as well as cancer, be it hematological, gynecological, lung, or other solid tumors. The construction is all set to begin in 2026.
- New AI along with advanced digital technology capabilities throughout the 5 existing manufacturing sites of GSK in North Carolina, Pennsylvania, and Maryland, as well as Montana.
- Novel drug substance manufacturing capacities
- New as well as elevated devices along with auto-injector capabilities as well as their assembly
Interestingly, with GSK to invest $30bn in the U.S. goes on to include the capital investments throughout the U.S. supply chain of GSAK as well as an increased investment within the R&D drug discovery, in addition to the development and clinical trial activity, as the U.S. anticipates to rank first across the world in terms of number of sites and studies as well as clinical trial participants taken care of by GSK in the forthcoming five years.
GSK has also committed new investments of almost $2 billion in U.S. manufacturing in the last year. Apparently, in October 2024, the construction started of a new $800 million facility at the Marietta, PA, site of GSK, therefore doubling the size as well as the capacity of the site. These new manufacturing investments are indeed going to create hundreds of highly skilled jobs, thereby building on almost a 15,000-strong U.S. workforce of GSK.
Emma Walmsley, the CEO of GSK, said that in addition to the many longstanding as well as major shared interests which connect the U.K. and the U.S., advancement in life sciences is sure to get ahead of disease. The state visit of the US president to the UK is indeed going to bring together both the countries which have actually led the world in science along with healthcare innovation. She added that with GSK to invest $30bn in the U.S., they are committing to invest it in the next 5 years, and hence they are going to further bolster the already robust R&D as well as the supply chain that they have in the country.
